Literature DB >> 1782740

Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies.

R W Jelliffe1, T Iglesias, A K Hurst, K A Foo, J Rodriguez.   

Abstract

The various components required for individualising clinical drug dosage regimens are reviewed, including a study of 3 types of fitting procedures, 2 types of gentamicin pharmacokinetic model and the utility of D-optimal times for obtaining serum gentamicin concentrations. The combination of the current Bayesian fitting procedure, the kslope pharmacokinetic model [in which the elimination rate constant (kel) can change from dose to dose with changing creatinine clearance] and the explicit measurement of the assay error pattern yielded predictions of future serum gentamicin concentrations which were (a) slightly better than those found using weighted nonlinear least squares; (b) somewhat better than those found with Bayesian fitting and a fixed-kel model; (c) better than those found using the traditional linear regression fitting procedure and a fixed kel model. D-Optimally timed pairs of concentrations also predicted future concentrations at least as well, and more cost effectively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1782740     DOI: 10.2165/00003088-199121060-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  16 in total

1.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Serum cardiac glycoside assay based upon displacement of 3 H-ouabain from Na-K ATPase.

Authors:  G Brooker; R W Jelliffe
Journal:  Circulation       Date:  1972-01       Impact factor: 29.690

3.  Reducation of digitalis toxicity by computer-assisted glycoside dosage regimens.

Authors:  R W Jelliffe; J Buell; R Kalaba
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

4.  An improved method of digoxin therapy.

Authors:  R W Jelliffe
Journal:  Ann Intern Med       Date:  1968-10       Impact factor: 25.391

5.  An improved method of digitoxin therapy.

Authors:  R W Jelliffe; J Buell; R Kalaba; R Sridhar; R Rockwell; J G Wagner
Journal:  Ann Intern Med       Date:  1970-04       Impact factor: 25.391

Review 6.  Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application.

Authors:  S Vozeh; J L Steimer
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

7.  Clinical studies with computer-assisted initial lidocaine therapy.

Authors:  J H Rodman; R W Jelliffe; E Kolb; D B Tuey; M F de Guzman; P W Wagers; L J Haywood
Journal:  Arch Intern Med       Date:  1984-04

8.  An evaluation of optimal sampling strategy and adaptive study design.

Authors:  G L Drusano; A Forrest; M J Snyder; M D Reed; J L Blumer
Journal:  Clin Pharmacol Ther       Date:  1988-08       Impact factor: 6.875

9.  Accuracy of Bayesian and Sawchuk-Zaske dosing methods for gentamicin.

Authors:  M E Burton; M S Chow; D R Platt; R B Day; D C Brater; M R Vasko
Journal:  Clin Pharm       Date:  1986-02

10.  A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients.

Authors:  G L Drusano; A Forrest; K I Plaisance; J C Wade
Journal:  Clin Pharmacol Ther       Date:  1989-06       Impact factor: 6.875

View more
  18 in total

1.  Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients.

Authors:  J Debord; J C Voultoury; G Lachatre; C Gay; J P Favereau; R Gay
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy.

Authors:  A A Vinks; J W Mouton; D J Touw; H G Heijerman; M Danhof; W Bakker
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Bayesian pharmacokinetic analysis of a gentamicin nomogram in neonates: a retrospective study.

Authors:  Robert E Ariano; Daniel S Sitar; Maria Davi; Sheryl A Zelenitsky
Journal:  Curr Ther Res Clin Exp       Date:  2003-03

4.  Pharmacoinformatics: equations for serum drug assay error patterns; implications for therapeutic drug monitoring and dosage.

Authors:  R W Jelliffe; B Tahani
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1993

Review 5.  Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?

Authors:  M M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients.

Authors:  Nicolas Charhon; Michael N Neely; Laurent Bourguignon; Pascal Maire; Roger W Jelliffe; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 7.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

9.  Studies on drug monitoring in thrice and once daily treatment with aminoglycosides.

Authors:  F Konrad; R Wagner; B Neumeister; H Rommel; M Georgieff
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Aminoglycoside monitoring in the once- or twice-daily era. The Dutch situation considered.

Authors:  R Janknegt
Journal:  Pharm World Sci       Date:  1993-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.